PT - JOURNAL ARTICLE AU - Bogdana Basina AU - Tetyana Pertseva AU - Lyudmyla Konopkina TI - Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level DP - 2013 Sep 01 TA - European Respiratory Journal PG - P3666 VI - 42 IP - Suppl 57 4099 - http://erj.ersjournals.com/content/42/Suppl_57/P3666.short 4100 - http://erj.ersjournals.com/content/42/Suppl_57/P3666.full SO - Eur Respir J2013 Sep 01; 42 AB - Aim. To optimized treatment therapy in COPD pts (in accordance with anti-inflammatory effects of inhalation corticosteroids (ICS) and bronchodilators) it’s very important to establish the phenotypes of COPD due to the severity of systemic inflammation (SI), and so to determine those markers, which may be demonstrative.Materials and methods. We studied 25 pts in stable phase (age – 63.3±4.1 yrs), divided into the groups according to the stage of COPD. All pts received an adequate therapy (due to GOLD). Measurements included clinical status, spirometry, CRP-level in plasma.Results. CRP-level in pts with COPD II was similar to the control, but in pts with COPD III and IV it was significantly higher.View this table:CRP-level in COPD pts according to stagesIn those time regardless of FEV1-level there were selected two subgroups of COPD pts due to CRP-level: 1st subgroup– with normal level of CRP (<7.0 mg/l), 2nd – with more higher one (>7.0 mg/l).View this table:CRP-level in COPD pts in subgroupsConclusion: CRP-level may be used to optimize anti-inflammatory therapy (including ICS) in COPD pts; also it may be a marker of early using of ICS by COPD pts. II stage, who have high CRP-level.